The Institute for Clinical and Economic Review (ICER) released a report this week that highlighted seven pharmaceuticals with “substantial price increases on top of already high current spending.” According to ICER, these seven agents accounted for billions in unnecessary expense in 2017 and 2018. AbbVie’s Humira® and Genentech’s Rituxan® topped the list, with Neulasta® coming … Continue reading Biosimilar Bytes This Week
Tag: price competition
$7.6 Billion Estimate on Savings Lost From Approved, Nonlaunched Biosimilars Could Be Low
$44 Billion by 2024. $250 Billion by 2024. Whatever. I’ve not been very impressed by the many attempts to estimate how much money biosimilars could save the US health care system. Even the more well-known estimates of biosimilar savings, like those from RAND and Express Scripts, have been little more than games of "pin the … Continue reading $7.6 Billion Estimate on Savings Lost From Approved, Nonlaunched Biosimilars Could Be Low
Udenyca to Launch January 3, Same WAC as Mylan’s Fulphila
Coherus Biosciences surprised many on its third-quarter earnings call late yesterday. It will rely not on a lower price than its biosimilar competitor to gain marketshare after Coherus' Udenyca launch, but on its ability to pull through on its patient and provider services and supply chain to gain significant marketshare for its biosimilar version of … Continue reading Udenyca to Launch January 3, Same WAC as Mylan’s Fulphila
A Third Biosimilar Adalimumab Approval in the US and Potentially Huge Humira Price Discount in Europe
The Food and Drug Administration (FDA) announced yesterday the approval of adalimumab-adaz from Sandoz. The new agent, dubbed Hyrimoz™, will not be launched in the US until 2023. The approval of Hyrimoz is the third for Sandoz (but only one, Zarxio®, is available for prescription in the US). The FDA approval of adalimumab-adaz covered several … Continue reading A Third Biosimilar Adalimumab Approval in the US and Potentially Huge Humira Price Discount in Europe
Scaling the Mountains to Create a Biosimilar Market Success
One of the persistent themes at the Association for Accessible Medicines’ first GRx+Biosims meeting was an existential one. Authorities such as Gillian Woollett, PhD; Hillel Cohen, PhD; and several industry experts worried that without a change in mindset and intervention by government, payers, and the industry itself, the US biosimilar industry may not survive its … Continue reading Scaling the Mountains to Create a Biosimilar Market Success
How Will Biosimilars Be Affected by Trump’s Drug Price Reform Measures?
When President Trump announced the broad strokes of his drug price reform initiative, some of these measures seemed on target to benefit the biosimilars industry. However long awaited, makers of originator biologics seemed not to be worried about its implications. The President may not be able to effect much change, without causing unintended adverse consequences. … Continue reading How Will Biosimilars Be Affected by Trump’s Drug Price Reform Measures?
Teva’s Syprine Generic Priced 14% Below Jacked Up Valeant Product Price
In an announcement that surprised few, Teva Pharmaceuticals announced that its generic version of trientine hydrochloride (Syprine®) for the treatment of Wilson’s disease will be sold for a very nongeneric price. Also unsurprising, Teva executives did not address the fact that the price of Syprine had been jacked up astronomically by Valeant Pharmaceuticals only recently, … Continue reading Teva’s Syprine Generic Priced 14% Below Jacked Up Valeant Product Price